Results 41 to 50 of about 589,499 (392)
Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease
Clinical Parkinsonism & Related Disorders, 2021 Introduction: Up to 40% of Parkinson’s disease patients taking dopamine agonist medication develop impulse control behaviors which can have severe negative consequences.
Alison Hall +5 more
doaj
Orexin-Corticotropin-Releasing Factor Receptor Heteromers in the Ventral Tegmental Area as Targets for Cocaine [PDF]
, 2015 Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegmental area (VTA) play an important role in stress-induced cocaine-seeking behavior.
Aguinaga, David +17 more
core +1 more source
PLoS ONE, 2019 Schizophrenia and Parkinson's disease can be controlled with dopamine antagonists and agonists. In order to improve the understanding of the reaction mechanism of these drugs, in this investigation we present a quantum chemical study of 20 antagonists ...
Ana Martínez +2 more
doaj +1 more source
Treatment of hyperprolactinemia: a systematic review and meta-analysis
Systematic Reviews, 2012 Background Hyperprolactinemia is a common endocrine disorder that can be associated with significant morbidity. We conducted a systematic review and meta-analyses of outcomes of hyperprolactinemic patients, including microadenomas and macroadenomas, to ...
Wang Amy T +14 more
doaj +1 more source
Characterisation of AmphiAmR11, an amphioxus (Branchiostoma floridae) D2-dopamine-like G protein-coupled receptor. [PDF]
PLoS ONE, 2013 The evolution of the biogenic amine signalling system in vertebrates is unclear. However, insights can be obtained from studying the structures and signalling properties of biogenic amine receptors from the protochordate, amphioxus, which is an ...
Asha L Bayliss, Peter D Evans
doaj +1 more source
Costs of Parkinson's Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study [PDF]
, 2010 Objective: Antiparkinsonian pharmacotherapy is costly and the determinants of drug costs in Parkinson's disease (PD) have been poorly investigated. The objective of this study was to investigate the costs of PD and antiparkinsonian drugs in an Italian ...
Balzer-Geldsetzer, Monika +10 more
core +1 more source
Endocrine Connections, 2018 The dopaminergic treatment represents the primary treatment in prolactinomas, which are the most common pituitary adenomas and account for about 40% of all pituitary tumours with an annual incidence of six to ten cases per million population.
Anastasia P Athanasoulia-Kaspar +2 more
doaj +1 more source
Nature Communications, 2020 Dopamine agonists increase brain glutathione levels. Here the authors identify noncanonical signalling by Nrf2 as a potential mechanism for the neuroprotective effects of dopamine D2 receptor activation.
Yao Wei +11 more
doaj +1 more source
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010. [PDF]
PLoS ONE, 2014 OBJECTIVE:Therapeutic options for Parkinson's disease mainly consist of L-dopa and dopamine agonists. However, in Japan, the product labeling of the ergot dopamine agonists, cabergoline and pergolide, was revised in April 2007 due to the risk of ...
Sachiko Nakaoka +6 more
doaj +1 more source
Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report
Frontiers in Psychiatry, 2022 Prolactinomas are the most prevalent functional pituitary adenomas. They are usually treated clinically with dopamine agonists. The most widely used and suitable drug is cabergoline (CAB), a specific D2 dopamine agonists.
Ana Carolina Correa e Castro +7 more
doaj +1 more source